30 June 2025 | 11:07AM CST Kingmed (603882.SS): China Healthcare Corporate Day 2025 — Key Takeaways: Policy pressures, operational challenges, cautious outlook We hosted Kingmed's IRD, Ms. Dongqi Xiao, with investors on Jun 25 at our China Healthcare Corporate Day 2025. Bottom line: Ms. Xiao mainly discussed: 1) Industry environment and policy impact; 2) Operating status and strategic response; and 3) Outlook and key initiatives. Key Takeaways Industry environment and policy impact: Multiple factors - inclu ...

30 June 2025 | 9:00AM JST Among back-end process stocks, which have relatively high AI exposure, investor interest in Advantest was particularly strong. We had much discussion about the company's earnings growth potential in FY3/26 and FY3/27, driven by expectations for expanding tester demand for ASICs in addition to GPUs. Meanwhile, for Disco, while concerns remain about near-term shipment momentum, many investors commented on the stock's increasing attractiveness relative to Advantest, considering its sh ...

Investment Rating - Buy: Hon Hai, Wiwynn, Wistron, Gigabyte, ASUS, AVC; Neutral: Quanta, Inventec [8] Core Insights - The average year-over-year revenue growth for ten companies in the AI servers and AI PCs supply chain is expected to be +37% in June 2025, +27% in July 2025, and +18% in August 2025, driven by the ramp-up of AI servers and new product launches [1] - Rack-level AI servers are transitioning models, which may impact revenue growth in the second half of 2025 [1] - Geopolitical uncertainties are causing changes in end market demand, leading to a slower month-over-month growth forecast of -6% in June, -8% in July, and +2% in August 2025 [1] Company Summaries Hon Hai - Expected 2Q25 revenues to grow 17% YoY to NT$1,813 billion, driven by AI server demand and tariff-related consumption pull-ins [13] - May revenues were 6% below estimates, affected by slower customer pull-in momentum and negative exchange rate impacts [13] - Maintain Buy rating with a target price of NT$242 based on a 14.9x 2026E P/E multiple [15] Quanta - Anticipated 2Q25 revenues to grow 57% YoY to NT$488 billion, supported by AI server ramp-up [20] - May revenues were 13% below estimates, with a decline in notebook shipments [20] - Maintain Neutral rating with a target price of NT$273 based on a 12.8x 2026E P/E [23] Wiwynn - Expected 2Q25 revenues to grow 161% YoY to NT$202 billion, driven by strong demand for ASIC AI servers [38] - May revenues were 34% higher than estimates, reflecting continued strong demand [39] - Maintain Buy rating with a target price of NT$3,838 based on a 20.5x 2026E P/E [42] Wistron - Expected June revenues to grow 123% YoY to NT$198 billion, driven by AI server demand [47] - Strong revenue in May, up 162% YoY, supported by new product cycles [44] - Maintain Buy rating with a target price of NT$152 based on a 14.8x 2026E P/E [49] Gigabyte - Expected 2Q25 revenues to grow 32% YoY to NT$97 billion, supported by AI servers and VGAs [50] - May revenues were 79% above estimates, reflecting tariff-related pull-ins [51] - Maintain Buy rating with a target price of NT$344 based on a 14.0x 2026E P/E [55] AVC - Expected 2Q25 revenues to grow 67% YoY to NT$27 billion, driven by liquid cooling business [27] - May revenues were higher than estimates, reflecting the rising trend in liquid cooling [27] - Maintain Buy rating with a target price of NT$878 based on a 20.0x 2026E P/E [37] ASUS - Expected 2Q25 revenues to grow 21% YoY to NT$175 billion, supported by AI and gaming PCs [57] - May revenues were up 41% YoY, exceeding estimates [62] - Maintain Buy rating with a target price of NT$849 based on a 14.6x 2026E P/E [63] Inventec - Expected June revenues to be similar to May, supported by AI server ramp-up [65] - Maintain Neutral rating with a focus on AI server revenue contribution [65]

Investment Rating - The report assigns a Neutral rating to Aier Eye Hospital with a 12-month target price of Rmb14, indicating a potential upside of 12.9% from the current price of Rmb12.4 [10][8]. Core Insights - Aier Eye Hospital is experiencing improvements in refractive surgery pricing due to new technologies, with a forecast of double-digit revenue growth for 2025 [2][7]. - The company anticipates a recovery in cataract surgery revenue growth to double digits in the second half of 2025, following price cuts of approximately 8-10% since the second half of 2024 [9][7]. - The overall ophthalmology market in China is expected to grow at a 12% CAGR from 2020 to 2030, driven by increased service upgrades and market penetration [7]. Summary by Sections Recent Trends - Growth in refractive surgeries slowed in April and May after a busy first quarter, but June showed improvement due to an increase in average selling prices (ASP) from new technologies [3]. - Cataract surgeries faced volume declines due to tightening reimbursement policies, while optometry performance remained moderate [3]. Refractive Surgery Pricing - New technologies such as SMILE 4.0 and SMILE pro have been launched, with SMILE 4.0 contributing 12% of refractive surgery revenue in Q1 2025 [3][6]. - The ASP for SMILE 4.0 is around Rmb18,800, with approximately 100 installations [3]. Cataract Surgery Outlook - The company expects cataract surgery revenue growth to recover to double digits in H2 2025, as the lower prices from H2 2024 are now reflected [9]. - Premium cataract surgeries accounted for 45%-50% of total cataract surgeries as of Q1 2025, with 15% of revenue coming from femtosecond laser-assisted surgeries [9]. Optometry Services - Recent pricing pressure on OK lenses was noted, particularly after public hospitals in Beijing reduced prices by 50% [9]. - The annualized cost for OK lenses is around Rmb10,000, while defocal lenses cost only Rmb2,000 to Rmb3,000 [9]. Overseas Expansion - Aier Eye Hospital is focusing on expanding its presence in South America [9].

Investment Rating - The report does not provide a specific investment rating for Conant Optical (2276.HK) as it is categorized as "Not Covered" [1]. Core Insights - Conant Optical is expanding its business from traditional spectacle lenses to AI/AR glasses, anticipating sustained growth in its core business and increased demand for AI/AR glasses due to their higher dollar content and specific client requirements [1][2]. - The company is positioned to benefit from the growing AI/AR glasses market, with expectations of a 56% CAGR in shipments in China from 2024 to 2030, reaching 7 million units by 2030 [2]. - Conant's customized lenses for AI/AR glasses are designed to be lighter and thinner, with a significant increase in average selling price (ASP) compared to traditional lenses [4]. Summary by Sections Company Profile - Conant Optical is a leading resin lenses manufacturer in China, with 44% of its revenues from standardized lenses, 37% from functional lenses, and 19% from customized lenses, which have a higher gross margin [3]. - The company operates in 90 countries and ranks among the top 10 resin lenses manufacturers globally by revenue [3]. Market Outlook - Management expresses optimism about the AI/AR glasses market's growth potential, indicating that Conant will be a key beneficiary due to its customized lens solutions for both global and local clients [8]. - The company plans to enhance its market presence by partnering with offline stores in China to facilitate the lens ordering process for consumers [8]. Production Capabilities - Conant has demonstrated strong mass production capabilities, allowing it to produce millions of customized lenses quickly, supported by its precision manufacturing skills [7]. - The company is expanding its production capacity with a new plant in Thailand expected to commence operations in 2026 [7].

Investment Rating - The report maintains a neutral asset allocation stance while focusing on diversification across regions and styles [3]. Core Insights - Increased expectations of a more dovish Federal Reserve and de-escalation of geopolitical tensions have created a favorable "Goldilocks" environment for markets, supporting growth pricing across various assets [1][2]. - The report highlights a broad geographical bullish growth repricing, with equities outperforming bonds and cyclicals outperforming defensives [1]. - Consensus EPS revisions have turned less negative recently, with positive revisions noted for the US market, indicating improved expectations for equity fundamentals [2]. Summary by Sections Market Conditions - The report indicates that markets are pricing in a more dovish Fed, with expectations for a rate cut brought forward to September and a reduced terminal rate forecast of 3-3.25% [1][7]. - The labor market data expected this Thursday is deemed critical for sustaining positive momentum, with economists forecasting 85k for non-farm payrolls, below the consensus of +113k [1]. Earnings Outlook - The upcoming Q2 earnings season is highlighted as a key focus, with a relatively low bar for EPS growth set at 4%, down from 12% in Q1, and insights expected on corporate adjustments to increased tariff rates [2]. Asset Allocation - The report suggests that reverse dispersion trades may be attractive as a macro hedge against potential growth deterioration over the summer [2]. - Recommendations include option hedges and specific strategies such as USD HY puts/CDS payers to hedge against stagflationary shocks [6]. Performance Metrics - The report provides forecasts for various asset classes, indicating expected total returns and downside risks for equities and bonds over different time horizons [18]. - The S&P 500 is projected to have a total return of -4.1% over 3 months, with a potential upside of 6.6% over 12 months [18]. Risk Appetite - The report notes a rebound in the Risk Appetite Indicator to 0.3, reflecting increased risk appetite among investors [1][26]. - Implied equity correlations have been falling, indicating expectations of more dispersion in the earnings season and a fading macro risk environment [2][15].

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The report highlights five key themes impacting the market, including macroeconomic factors, currency dynamics, oil market conditions, and tariff developments [1][2][5][20][29] Summary by Sections Macroeconomic Insights - The UK is positioned as a higher-growth, higher-inflation jurisdiction compared to G10 peers, with terminal rates likely settling 100-200 basis points above Europe [2][3] - Business confidence in the UK is at multi-month highs, and there is a deep sovereign bond market with long-term investors under-invested [2][3] Currency Dynamics - The USD may weaken further due to a dovish tilt from the Fed, especially if upcoming labor market data shows weakness [5][6] - The Euro area is experiencing equity inflows, which may lead to a stronger Euro, although the pace could slow if there are no compelling reasons to reallocate from the US [7][8] - The JPY is expected to maintain demand due to recession risks and reduced appeal of US assets, while the INR may lag in appreciation compared to other Asian currencies [9][13] Oil Market Analysis - The risk premium in oil prices has significantly decreased, dropping from over $15 per barrel to just a few dollars, as geopolitical risks have lessened [20][21] - The report forecasts Brent crude oil prices to decline from the current high 60s to around $60 in Q4 and mid-50s by 2026, driven by oversupply [23][24] - Global oil inventories have increased by approximately 1.3 million barrels per day over the last 90 days, supporting the forecast of an oversupplied market [27][28] Tariff Developments - The July 9 tariff deadline is likely to be pushed out, with potential for sectoral tariffs rather than broad increases [29][30] - The report suggests that specific sectors, such as semiconductors and pharmaceuticals, may face targeted tariffs, but the timing remains uncertain [35][36]

Investment Rating - The report does not explicitly provide an investment rating for the industry or the specific company, SenseTime Core Insights - The management of SenseTime is optimistic about the increasing demand for generative AI solutions from enterprise clients, emphasizing their capability to deliver a comprehensive one-stop solution that includes infrastructure, software migration services, foundational models, and applications [1][4][7] - SenseTime's generative AI products have shown triple-digit year-over-year growth in 2024, contributing 64% to the total revenue, indicating strong market traction [4][8] - The company is also expanding its generative AI applications, targeting various sectors including productivity tools and interactive AI tools, with significant engagement metrics reported [8][9] Summary by Sections Generative AI Solutions - SenseTime is positioned to provide a complete generative AI solution, from infrastructure to foundational models and applications, which is crucial for enterprise clients looking to implement AI effectively [1][4][7] - The company has developed an in-house large-scale AI data center (AIDC) in Shanghai, enhancing its operational capabilities and software migration processes [7] Market Engagement - SenseTime's generative AI applications have penetrated major enterprises such as Kingsoft Office, China Mobile, and Lenovo, with daily API calls exceeding 3.5 billion, showcasing the high demand for their tools [8] - The company has also launched multiple AI interactive tools, achieving high engagement and conversion rates, indicating successful commercialization strategies [8] Automotive Solutions - In 2024, SenseTime's automotive solutions empowered 42 new car models, and the company is collaborating with major automotive manufacturers to deploy advanced AI functionalities [9] - The expectation is set for mass production of their intelligent driving solutions on NVIDIA's Thor platform by the end of 2025, reflecting a strong pipeline for future growth in the automotive sector [9]

Investment Rating - The investment rating for China Resources Pharmaceuticals is Neutral with a 12-month price target of HK$6.17, representing an upside potential of 18.8% from the current price of HK$5.19 [8][29]. Core Insights - The company is experiencing soft growth in the first half of the year, leading management to lower previous guidance of double-digit year-on-year sales growth for 2025, pending a recovery in the second half [1][2]. - The distribution business is facing challenges due to a tough industry environment, and there are no clear signals of growth recovery as the national medical reimbursement fund remains tight [2][3]. - Cash collection is under pressure, with hospitals' financial positions still strained, resulting in delayed payments for non-VBP products despite some acceleration in cash collection for VBP products [3]. Summary by Sections Financial Performance - Revenue for 2025 is projected to be HK$271.5 billion, with a 5-year EPS CAGR of 10% for the manufacturing business and 5% for the distribution business [7]. - The company’s market cap is HK$32.6 billion, with an enterprise value of HK$133.8 billion [8]. Business Segments - The manufacturing business is valued at HK$31.4 billion, while the distribution business is valued at HK$4.1 billion [7]. - Specific challenges include slower growth for Sanjiu due to a high base, pressure on Boya from albumin VBP, and a softer growth trajectory for plasma collection [2]. Cash Management - To alleviate cash pressure, the company is managing its cash cycle actively, including de-prioritizing high-risk regions for receivables [3].

更多资料加入知识星球：水木调研纪要 关注公众号：水木Alpha 29 June 2025 | 7:20PM BRT Global Metals & Mining: Takeaways from GS Global Copper Week 2025 +55(11)3371-4580 | marcio.farid@gs.com Goldman Sachs do Brasil CTVM S.A. Matt Greene +44(20)7051-0489 | matt.greene@gs.com Goldman Sachs International Mike Harris +1(713)654-8481 | mike.harris@gs.com Goldman Sachs & Co. LLC Emerson Vieira +55(11)3372-0256 | emerson.vieira@gs.com Goldman Sachs do Brasil CTVM S.A. Henrique Marques +55(11)3371-0778 | henrique.marques@gs.com Goldman Sachs ...